Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Status:
Completed
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after
allogeneic hematopoietic stem cell transplantation (HSCT). We sought to evaluate the effect
and safety of ruxolitinib (RUX) add-on in the treatment of patients with SR-GVHD.